Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 268

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 268
---
 fiscal year at our next annual shareholders’ meeting. If approved, this dividend will be paid on May 15, 2025. We expect that we will continue to pay regular dividends based on our financial condition and results of operations. The proposed 2024 dividend equates to a distribution of 55.0 % of our business net income. For information on the non-IFRS financial measure “business earnings per share” see “Item 5. Operating and Financial Review and Prospects — Business Net Income .” The following table sets forth information with respect to the dividends paid by our Company in respect of the 2020 , 2021 , 2022 and 2023 fiscal years and the dividend that will be proposed for approval by our shareholders in respect of the 2024 fiscal year at our April 30, 2025 shareholders’ meeting.

|                        | 2024 | -a | 2023 | 2022 | 2021 | -b | 2020 |
| Dividend per Share (€) | 3.92 |    | 3.76 | 3.56 | 3.33 |    | 3.20 |

(a) Proposal, subject to shareholder approval. (b) Plus a dividend in kind of EUROAPI shares, at a ratio of one EUROAPI share per 23 Sanofi shares. The declaration, amount and payment of any future dividends will be determined by majority vote of the holders of our shares at an ordinary general meeting, following the recommendation of our Board of Directors. Any declaration will depend on our results of operations, financial condition, cash requirements, future prospects and other factors deemed relevant by our shareholders. Accordingly, we cannot assure you that we will pay dividends in the future on a continuous and regular basis. Under French law, we are required to pay dividends approved by an ordinary general meeting of shareholders within nine months following the meeting at which they are approved. Disclosure pursuant to Section 13(r) of the United States Exchange Act of 1934 Sanofi engages in limited business activities with Iran related to human health products – namely, sales of bulk and branded pharmaceuticals and vaccines. These activities, which are disclosed pursuant to Section 13(r) of the United States Exchange Act of 1934, as amended, are not financially material to Sanofi and contributed well under 1% of Sanofi’s consolidated net sales in 2024 . Sanofi’s US affiliates and non-US affiliates owned or controlled by Sanofi’s US affiliates either do